GT Biopharma

GT Biopharma EBITDA per Share

The EBITDA per Share of GT Biopharma (GTBP) as of Nov 5, 2026 is -56.34 USD. In the previous year, EBITDA per Share was -189.25 USD — a change of -70.23% (higher).

EBITDA per Share

-56.34USD

YoY

-70.23%

Last updated:

EBITDA per Share of GT Biopharma is 2025 -56.34 USD. EBITDA per Share of GT Biopharma was 2024 -189.25 USD. It decreases by -70.23% higher compared to the previous year.

The GT Biopharma EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-2,080.44 USD
Jan 1, 2019
-221.46 USD
Jan 1, 2020
-1.30 USD
Jan 1, 2021
-166.23 USD
Jan 1, 2022
-449.41 USD
Jan 1, 2023
-245.94 USD
Jan 1, 2024
-189.25 USD
Jan 1, 2025
-56.34 USD
The GT Biopharma EBITDA per Share history
YEAREBITDA per ShareYoY
-56.34USD-70.23%
-189.25USD-23.05%
-245.94USD-45.27%
-449.41USD+170.36%
-166.23USD+12,723.71%
-1.30USD-99.41%
-221.46USD-89.36%
-2,080.44USD+80.93%
-1,149.87USD-93.87%
-18,748.00USD+614.05%
-2,625.59USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

GT Biopharma Stock analysis

What does GT Biopharma do? GT Biopharma Inc, based in Brisbane, California, is a clinical-stage biopharmaceutical company operating in the Health Care sector. The company focuses on developing immuno-oncology therapeutics using its proprietary TriKE NK cell engager platform, which enhances natural killer cells to target cancer. It employs two full-time staff and is listed on the stock market since October 22, 2013. Its lead product, GTB-3550, is a tri-specific fusion protein for CD33-expressing cancers, currently in Phase 1 clinical trials. GT Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GT Biopharma stock

EBITDA per Share of GT Biopharma is -56.34 USD in 2025.

EBITDA per Share of GT Biopharma changed from -189.25 USD to -56.34 USD, representing a -70.23% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share GT Biopharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — GT Biopharma

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — GT Biopharma